IV Famotidine Dosing
The standard adult IV dose of famotidine is 20 mg every 12 hours, administered either as a slow IV push over at least 2 minutes or as a 15-30 minute infusion 1.
Adult Dosing
Standard Dosing
- 20 mg IV every 12 hours for hospitalized patients with peptic ulcer disease, GERD, or those unable to take oral medication 1
- Administer as:
Pathological Hypersecretory Conditions
- Start with 20 mg IV every 12 hours 1
- Adjust based on individual patient response; some patients have required oral doses up to 160 mg every 6 hours for severe Zollinger-Ellison Syndrome 1
Pediatric Dosing (Ages 1-16 Years)
The recommended starting dose is 0.25 mg/kg IV every 12 hours, up to a maximum of 40 mg/day 1.
- Administer over at least 2 minutes as IV push or as a 15-minute infusion 1
- Published studies support doses up to 0.5 mg/kg IV every 12 hours for adequate acid suppression 1, 2
- No data available for infants under 1 year of age 1
- Individualize treatment duration and dose based on clinical response, gastric pH monitoring, or endoscopy 1
Renal Impairment Adjustments
For patients with moderate to severe renal insufficiency (creatinine clearance <50 mL/min), reduce the dose to half or prolong the dosing interval to 36-48 hours 1.
Specific Recommendations by Renal Function:
- CrCl >60 mL/min: Standard dosing (20 mg every 12 hours) 3
- CrCl 30-60 mL/min (moderate impairment): Reduce dose by 50% or extend interval 1, 3
- CrCl <30 mL/min (severe impairment): Reduce dose by 75% or extend interval to 36-48 hours 1, 3
- Elimination half-life can exceed 20 hours, reaching approximately 24 hours in anuric patients 1
Critical Considerations for Renal Impairment:
- Famotidine is 70% renally eliminated unchanged, primarily via tubular secretion 4
- CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, making dose reduction essential to avoid drug accumulation 1
- The renal clearance of famotidine (310 mL/min in normal subjects) far exceeds glomerular filtration rate, confirming significant tubular secretion 5
- Pediatric patients with renal impairment should also receive dosage adjustments based on similar principles 1
Safety Notes
Recent pediatric data from 2024 demonstrates that undiluted IV push administration of famotidine (doses ≥5 mg) produced no clinically significant hemodynamic adverse effects in critically ill pediatric patients 6. Only 3.4% of patients required vasoactive medication adjustments, and these were postoperative cardiac surgery patients with pre-existing hemodynamic instability 6. This contradicts historical adult concerns about rapid administration causing hypotension.
Common pitfall: Failing to adjust dosing in renal impairment can lead to drug accumulation and CNS side effects due to the prolonged elimination half-life (up to 24 hours in anuric patients versus 2-4 hours in normal renal function) 1, 4.